Scholar Rock's apitegromab (Isembyld) has received FDA fast track designation for facioscapulohumeral muscular dystrophy (FSHD), a rare inherited condition that causes progressive, often asymmetric muscle weakness in the face, shoulders, arms, and lower extremities. The designation comes alongside the launch of participant dosing in the phase 2 FORGE trial, signaling momentum for a disease that has historically had no approved therapies — only supportive care.

The FORGE trial is a randomized, double-blind, placebo-controlled study enrolling approximately 60 adults with genetically confirmed FSHD. Participants will receive apitegromab 10 mg/kg or placebo intravenously every 4 weeks for 52 weeks, with the primary endpoint being percent change in total lean muscle volume measured by MRI. Preclinical data from mouse models showed the drug increased muscle mass, strength, and endurance — a promising signal for human trials.

Apitegromab works by blocking myostatin, a protein that limits muscle growth, and was recently approved for spinal muscular atrophy (SMA) — the first FDA-approved therapy to directly target muscle loss in that disease.

Key Takeaways:

• Fast track and orphan drug designations have both been granted, underscoring the unmet need in FSHD
• Primary endpoint: percent change in lean muscle volume by MRI at 52 weeks
• Apitegromab's SMA approval, supported by phase 3 SAPPHIRE trial data, provides clinical proof-of-concept for the myostatin-inhibition mechanism

Why it matters: FSHD affects an estimated 1 in 8,000 people worldwide, yet no disease-modifying treatments exist. Fast track status could accelerate the path to approval, offering real hope to a community that has long waited for targeted therapies.